Education

Ph.D. in Pharmacology,University of Washington, Department of Pharmacology, Seattle, WA, 1996

Current Position

Primary appointments
Associate Professor, General Medical Sciences-Oncology, Case Western Reserve University, Cleveland, OH. Primary Appointment with Tenure (6/2010 -to date)
Co-Director, Breast Cancer Program, Case Comprehensive Cancer Center, Cleveland, OH (6/2010 - to date)
Leader, TME & Metastasis Focus Group, Case Comprehensive Cancer Center, Cleveland, OH (7/2013 - to date)

Secondary appointments
Associate Professor, Dept. of Pharmacology, CWRU, Cleveland, OH. Secondary Appointment and Training Faculty Member (6/2010 - to date)
Associate Professor, Cancer Biology Training Program, CWRU, Cleveland, OH. Training Faculty Member (6/2010 - to date)
Scientific Advisory Board, Oncomatrix Inc., Bilbao, Spain (6/2012 - to date)

Publications

Papers published in refereed journals (since 2008)

1. Lee, Y-H. and Schiemann, W.P. (2014). Chemotherapeutic targeting of the transforming growth factor- pathway in breast cancers. Breast Cancer Manage. 2: in press.
   
2. Taylor, M.T., Davuluri, G., Parvani, J.P., Wendt, M.K., Plow, E.F., Schiemann, W.P.* and Sossey-Alaoui, K.* (2014) WAVE3 is required for TGF-β-mediated EMT and metastasis. (submitted). Breast Cancer Res Treat. 159: in press. *Co-corresponding Authors.
   
3. Peiris, P. M., Toy, R., Abramowski, A., Vicente, P., Tucci, S., Bauer, L., Mayer, A., Tam, M., Doolittle, E., Pansky, J., Tran, E., Lin, D., Schiemann, W. P., Ghaghada, K. B., Griswold, M. A. and Karathanasis, E. (2013). Treatment of cancer micrometastasis using a multicomponent chain-like nanoparticle. J Control Release 173C: 51-58.
   
4. Wendt, M.K. and Schiemann, W.P. (2013). Longitudinal bioluminescent quantification of three dimensional cell growth. Bio-protocol, 3(23):http:// www.bio-protocol.org/wenzhang.aspx?id=993.
   
5. Parvani, J. G. and Schiemann, W. P. (2013). Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. Breast Cancer Res 15(4): R72. *Highly Accessed
   
6. Parvani, J. G., Galliher-Beckley, A. J., Schiemann, B. J. and Schiemann, W. P. (2013). Targeted inactivation of beta1 integrin induces beta3 integrin switching, which drives breast cancer metastasis by TGF-beta. Mol Biol Cell 24(21): 3449-3459.
   
7. Balanis, N., Wendt, M. K., Schiemann, B. J., Wang, Z., Schiemann, W. P.* and Carlin, C. R.* (2013). Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem 288(25): 17954-17967. *Co-corresponding authors. *Featured in “Breaking Advances – Highlights from Recent Cancer Literature” in Cancer Res (2012, vol 73:4172).
   
8. Morrison, C. D., Parvani, J. G. and Schiemann, W. P. (2013). The relevance of the TGF-beta Paradox to EMT-MET programs. Cancer Lett 341(1): 30-40. *7 consecutive months as a “Top 25” download from the Journal Website.
   
9. Taylor, M. A., Sossey-Alaoui, K., Thompson, C. L., Danielpour, D. and Schiemann, W. P. (2013). TGF-beta upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest 123(1): 150-163.
   *Top Story in “Mammary Cell News” volume 4.50, December 20, 2012.
   *Featured in MDLinx.com (12/12); EurekAlert (12/12); Cleveland Jewish News (12/12); ScienceDaily (12/12); ScienceNewsline (12/12); News Medical (12/12), Health Canal (12/12); Futurity.org (12/12); The Cleveland Leader (12/12); Biotech Daily (1/13); and NewsRX (1/13).
   *Featured in “Viewpoint” in Breast Cancer Res (2013) 15:305.
   *Featured in “News & Views – Research Highlights” in Biomarkers in Medicine (2013) 7:204
   
10. Wendt, M. K., Schiemann, B. J., Parvani, J. G., Lee, Y. H., Kang, Y. and Schiemann, W. P. (2013). TGF-beta stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer. Oncogene 32(16): 2005-2015.*Top Story in “Mammary Cell News” volume 4.24, June 21, 2012. *Featured in MDLinx.com (6/12).
    
11. Wendt, M. K., Tian, M. and Schiemann, W. P. (2012). Deconstructing the mechanisms and consequences of TGF-beta-induced EMT during cancer progression. Cell Tissue Res 347(1): 85-101. *Cover and Featured Article.
    
12. Taylor, M. A., Lee, Y. H. and Schiemann, W. P. (2011). Role of TGF-beta and the tumor microenvironment during mammary tumorigenesis. Gene Expr 15(3): 117-132.
    
13. Balanis, N., Yoshigi, M., Wendt, M. K., Schiemann, W. P. and Carlin, C. R. (2011). beta3 integrin-EGF receptor cross-talk activates p190RhoGAP in mouse mammary gland epithelial cells. Mol Biol Cell 22(22): 4288-4301.
    
14. Yori, J. L., Seachrist, D. D., Johnson, E., Lozada, K. L., Abdul-Karim, F. W., Chodosh, L. A., Schiemann, W. P. and Keri, R. A. (2011). Kruppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia 13(7): 601-610.
    
15. Raju, R., Nanjappa, V., Balakrishnan, L., Radhakrishnan, A., Thomas, J. K., Sharma, J., Tian, M., Palapetta, S. M., Subbannayya, T., Sekhar, N. R., Muthusamy, B., Goel, R., Subbannayya, Y., Telikicherla, D., Bhattacharjee, M., Pinto, S. M., Syed, N., Srikanth, M. S., Sathe, G. J., Ahmad, S., Chavan, S. N., Kumar, G. S., Marimuthu, A., Prasad, T. S., Harsha, H. C., Rahiman, B. A., Ohara, O., Bader, G. D., Sujatha Mohan, S., Schiemann, W. P. and Pandey, A. (2011). NetSlim: high-confidence curated signaling maps. Database (Oxford) 2011: bar032.
    
16. Wendt, M. K., Taylor, M. A., Schiemann, B. J. and Schiemann, W. P. (2011). Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer. Mol Biol Cell 22(14): 2423-2435. *See Faculty of 1000 (http://f1000.com/11598960#evaluations)
    
17. Wendt, M. K., Molter, J., Flask, C. A. and Schiemann, W. P. (2011). In vivo dual substrate bioluminescent imaging. J Vis Exp(56).
    
18. Parvani, J. G., Taylor, M. A. and Schiemann, W. P. (2011). Noncanonical TGF-beta signaling during mammary tumorigenesis. J Mammary Gland Biol Neoplasia 16(2): 127-146. *6 consecutive months as a “Top 5” download from the Journal Website.
    
19. Taylor, M. A., Amin, J. D., Kirschmann, D. A. and Schiemann, W. P. (2011). Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-beta signaling in breast cancer cells. Neoplasia 13(5): 406-418.*Cover and Featured Article
    
20. Tian, M., Neil, J. R. and Schiemann, W. P. (2011). Transforming growth factor-beta and the hallmarks of cancer. Cell Signal 23(6): 951-962.
    
21. Tobi, M., Kim, M., Zimmer, R., Hatfield, J., Kam, M., Khoury, N., Carville, A., Lawson, M. J., Schiemann, W. P. and Thomas, P. (2011). Colorectal cancer in the cotton top tamarin (Saguinus oedipus): how do they evade liver metastasis? Dig Dis Sci 56(2): 397-405.
    
22. Lee, Y. H. and Schiemann, W. P. (2011). Fibromodulin suppresses nuclear factor-kappaB activity by inducing the delayed degradation of IKBA via a JNK-dependent pathway coupled to fibroblast apoptosis. J Biol Chem 286(8): 6414-6422.
    
23. Allington, T. M. and Schiemann, W. P. (2011). The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-beta in mammary epithelial cells. Cells Tissues Organs 193(1-2): 98-113.
    
24. Micalizzi, D. S., Wang, C. A., Farabaugh, S. M., Schiemann, W. P. and Ford, H. L. (2010). Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth. Cancer Res 70(24): 10371-10380.
    
25. Wendt, M. K., Smith, J. A. and Schiemann, W. P. (2010). Transforming growth factor-beta-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29(49): 6485-6498. *Featured in “Mammary Cell News” volume 2.33, September 2, 2010.
    
26. Taylor, M. A., Parvani, J. G. and Schiemann, W. P. (2010). The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells. J Mammary Gland Biol Neoplasia 15(2): 169-190.*23 consecutive months as a “Top 5” download from the Journal Website.
    
27. Peng, A., Lewellyn, A. L., Schiemann, W. P. and Maller, J. L. (2010). Repo-man controls a protein phosphatase 1-dependent threshold for DNA damage checkpoint activation. Curr Biol 20(5): 387-396. *See Faculty of 1000 (http://f1000.com/3199956#evaluations)
    
28. Tian, M. and Schiemann, W. P. (2010). PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-beta signaling during mammary tumorigenesis. FASEB J 24(4): 1105-1116.
    
29. Wendt, M. K., Smith, J. A. and Schiemann, W. P. (2009). p130Cas is required for mammary tumor growth and transforming growth factor-beta-mediated metastasis through regulation of Smad2/3 activity. J Biol Chem 284(49): 34145-34156. *See Faculty of 1000 (http://f1000.com/1168476#evaluations)
    
30. Wendt, M. K., Allington, T. M. and Schiemann, W. P. (2009). Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 5(8): 1145-1168.
    
31. Keshamouni, V. G. and Schiemann, W. P. (2009). Epithelial-mesenchymal transition in tumor metastasis: a method to the madness. Future Oncol 5(8): 1109-1111.
    
32. Wendt, M. K. and Schiemann, W. P. (2009). Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis. Breast Cancer Res 11(5): R68. *Highly Accessed.
    
33. Tian, M. and Schiemann, W. P. (2009). The TGF-beta paradox in human cancer: an update. Future Oncol 5(2): 259-271.
    
34. Allington, T. M., Galliher-Beckley, A. J. and Schiemann, W. P. (2009). Activated Abl kinase inhibits oncogenic transforming growth factor-beta signaling and tumorigenesis in mammary tumors. FASEB J 23(12): 4231-4243.
    
35. Micalizzi, D. S., Christensen, K. L., Jedlicka, P., Coletta, R. D., Baron, A. E., Harrell, J. C., Horwitz, K. B., Billheimer, D., Heichman, K. A., Welm, A. L., Schiemann, W. P. and Ford, H. L. (2009). The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest 119(9): 2678-2690.
    
36. Neil, J. R., Tian, M. and Schiemann, W. P. (2009). X-linked inhibitor of apoptosis protein and its E3 ligase activity promote transforming growth factor-{beta}-mediated nuclear factor-{kappa}B activation during breast cancer progression. J Biol Chem 284(32): 21209-21217.
    
37. Tian, M. and Schiemann, W. P. (2009). Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor Beta in breast cancer. Transl Oncol 2(3): 174-183.
    
38. Neil, J. R., Johnson, K. M., Nemenoff, R. A. and Schiemann, W. P. (2008). Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-beta through a PGE2-dependent mechanisms. Carcinogenesis 29(11): 2227-2235.
    
39. Lee, Y. H., Albig, A. R., Regner, M., Schiemann, B. J. and Schiemann, W. P. (2008). Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis 29(12): 2243-2251.
    
40. Xiao, Y. Q., Freire-de-Lima, C. G., Schiemann, W. P., Bratton, D. L., Vandivier, R. W. and Henson, P. M. (2008). Transcriptional and translational regulation of TGF-beta production in response to apoptotic cells. J Immunol 181(5): 3575-3585.
    
41. Albig, A. R., Becenti, D. J., Roy, T. G. and Schiemann, W. P. (2008). Microfibril-associate glycoprotein-2 (MAGP-2) promotes angiogenic cell sprouting by blocking notch signaling in endothelial cells. Microvasc Res 76(1): 7-14.
    
42. Neil, J. R. and Schiemann, W. P. (2008). Altered TAB1:I kappaB kinase interaction promotes transforming growth factor beta-mediated nuclear factor-kappaB activation during breast cancer progression. Cancer Res 68(5): 1462-1470.
    
43. Galliher-Beckley, A. J. and Schiemann, W. P. (2008). Grb2 binding to Tyr284 in TbetaR-II is essential for mammary tumor growth and metastasis stimulated by TGF-beta. Carcinogenesis 29(2): 244-251.
    

Books chapters

1. Buxton, I.L.O., Westfall, D.P. and Schiemann, W.P. (1991) “A role for adenosine in myometrial function?” in Role of adenosine and adenine nucleotides in the biological system. Edited by S. Imai and M. Nakazawa, pp. 499-506, Elsevier, Amsterdam.
   
2. Schiemann, W.P. (2006) “FBLN-5”. AfCS-Nature Signaling Gateway Molecule Pages. Molecule Page, A003396.
   
3. Wendt, M.K., Allington, T.M. and Schiemann, W.P. (2008). “Regulation of epithelial-mesenchymal transition by TGF in normal and malignant cells” in Human Epithelial Tumor Cell Plasticity: Implications for Cancer Progression and Metastasis. Research Signpost Press. ISBN: 978-81-308-0275-6. Edited by P.J. Higgins. Chapter 9, 155-180.
   
4. Lee, Y-H. and Schiemann, W.P. (2012) “Fibulins.” Encyclopedia of Signaling Molecules. Edited by S. Choi. Springer, India. 1st Edition. Part 7, pages 616-623. DOI: 10.1007/978-1-4419-0461-4_565.
   
5. Wendt, M.K. and Schiemann, W.P. (2012) “Microenvironmental regulation of TGF-signaling during metastatic progression” in Signalling Pathways and Molecular Mediators in Metastasis. Springer. ISBN: 978-94-0007-2557-7. Edited by Alessandro Fatatis. Chapter 5, 115-141.
   
6. Wendt, M.K. and Schiemann, W.P. (2013) “The multifunctional roles of TGF-in navigating the metastatic cascade” in TGF in Human Disease. Springer. Edited by Aris Moustakas and Kenji Miyazawa.
   

Non-refereed publications

1. Schiemann, B. (2011) Canine cancer and clinical trials. “Health Matters” Column, The Weimaraner Magazine, Weimaraner Club of America. July Issue, pages 36-38.
   
2. Schiemann, B. (2012) Canine mammary tumors. “Health Matters” Column, The Weimaraner Magazine, Weimaraner Club of America. July Issue, pages 12-15.